Chapter from the book *Psychiatric Disorders - Trends and Developments*

Downloaded from: http://www.intechopen.com/books/psychiatric-disorders-trends-and-developments

Interested in publishing with InTechOpen?
Contact us at book.department@intechopen.com
Neurocognitive Expression of Hypofrontality in Long Term Schizophrenia

Marek Krzystanek¹, Irena Krupka-Matuszczyk¹ and Adam Klasik²

¹Department of Psychiatry and Psychotherapy, Medical University of Silesia in Katowice
²The Institute of Psychology, Opole University
Poland

1. Introduction

Despite over a century of studies on schizophrenia, its pathogenesis still remains unexplained. In particular, cognitive dysfunctions, related to a decrease of prefrontal cortex activity in the human brain represent one of the main symptoms of schizophrenia. The cognitive dysfunctions usually precede, by a few years, the first acute episode of the disease. These dysfunctions are present in approximately 70% of persons suffering from schizophrenia, and can be maintained at a stable level over the rest of their lifetime (Rund et al., 2006). For instance, majority of patients enrolled in the CATIE study suffered from the cognitive disorders (Lieberman et al., 2005a).

According to Javitt (2010), the cognitive deficits are the key symptoms of schizophrenia, which usually precede an onset of some other symptoms of this disease. Due to that, the cognitive disorders can represent the leading concept among hypotheses, related to etiology of schizophrenia. The main component of these disorders is the deterioration of attention concentration and operative memory deficits, including the difficulty of holding some elements in short-term memory (Goldman-Rakic, 1999) that in turn translates into some cognitive dysfunctions. These disorders include also memory, learning abilities, and executive functions (Meltzer & McGurk, 2004). The cognitive dysfunctions related to hypofrontality consist of deterioration of the activity of prefrontal brain cortex (Carter et al., 1998).

In majority of patients, the cognitive deficits begin prior to their first disease episode, in the prodromal stage (Fuller et al., 2002). Individuals with prodromal schizophrenia symptoms often present deficits, ranging in intensity from almost normal conditions to the ones, resembling mental status of patients with the first episode of their disease (Lencz et al., 2006). In this aspect, neurocognitive disorders can be considered as the initial schizophrenia symptoms (Javitt, 2010). Due to these reasons, the cognitive disorders appear to be closely connected with the etiology of schizophrenia (Kantrowitz & Javitt, 2010b).

In schizophrenia, the cognitive dysfunctions and hypofrontality are associated with hypofunction of NMDA receptors (NMDA-R) (Marek et al., 2010), and according to Carlsson (2006), an abnormal function of NMDA-R is the main cause of schizophrenia. These cognitive disorders, mostly in form of concentration deterioration, and deficits of operative memory are results of prefrontal cortex dysfunctions, which are related to the...
deficit of glutamergic transmission, caused by the NMDA-R hypofunction (Thomsen et al., 2009).

There are two pharmacological models of the NMDA-R (receptor) hypofunction – acute and chronic (Pratt et al., 2008). Acute receptor antagonist model relates to a short-term administration of the NMDA-R antagonist. In this situation, blocking the NMDA-R causes disinhibition of neurotransmission and so called hyperfrontality that means increased glutamergic activity in the areas of prefrontal cortex (Homayoun & Moghaddam, 2007). There is indirect evidence that some cerebral metabolic disorders, in the acute phase of schizophrenia, resemble the changes that were observed experimentally, during administration of the NMDA-R antagonists, directly to different areas of the brain (Bubeníková-Valesová et al., 2008). Also, a significant increase of the glutaminic acid concentration in the cingular area has been noted both in patients with an early psychosis (Théberge et al., 2002), and with prodromal schizophrenia symptoms (Stone et al., 2009). Pratt et al. (2008) proposed a chronic psychedelic (PCP) model, which explains a relation between the NMDA receptors hypofunction and hypofrontality. Chronic administration of the PCP to rats caused a reduction of glucose metabolism in their prefrontal cortex, and a decrease in the expression of protein marker of gamma aminobutyric acid (GABA) interneuron’s’ activity. In schizophrenia patients, similarly to chronic PCP abusers, the hypofrontality symptoms and GABA interneuron’s deficits have been noted. According to the Pratt’s model, hypofrontality represents neuroadaptation, created during a period of long-term glutamergic hyperfunction, caused by a chronic blockage of the NMDA-R, related to GABA interneurons.

Based on some studies, the cognitive deficits appear a few years prior to the onset of schizophrenia (Fuller et al., 2002; Kantrowitz et Javitt, 2010b), but there is no convincing evidence that they are present since early childhood (Paz et al., 2008; Perkins et al., 2005). A 28-year observational study by Seidman et al. (2006) has revealed that the patients with schizophrenia displayed some minor concentration disorders already at the age of 7 years. These disorders are subsequently aggravated, with the development of the disease. However, the exact moment of aggravation is still unknown. It is possible that the disorders’ exacerbation can occur just before the first schizophrenia episode.

2. Study design

Our unpublished study results indicate the persistence of cognitive dysfunctions in schizophrenia, and are convergent with some recent research data in this area.
In our study, cognitive functioning was assessed with neuropsychological tests, included in the Vienna System Tests. Functions of attention, operational memory, learning and motor reactions were also examined. A battery of Cognition (COG), Block Taping Test (CORSI), SIGNAL and Reaction Test (RT) tests was performed in all of our paranoid schizophrenia patients.

3. Study group

We studied a group of 162 paranoid schizophrenics, treated with 3 different neuroleptics, or treatment-resistant patients (Figure 1).
Patients who were recruited to this study were diagnosed with paranoid schizophrenia, and treated in monotherapy with one of the following neuroleptics: haloperidol, clozapine or...
olanzapine. Subjects in the study group met the contemporary criteria of symptomatic remission in schizophrenia. The study covered also a group of chronically ill schizophrenic subjects, who were resistant to the pharmacologic treatment, and did not have the remission.

![Pie chart](image1.png)

Fig. 1. Percentages of paranoid schizophrenia patient’s sub-groups, treated with haloperidol, clozapine, olanzapine, and treatment-resistant. Results are shown as percentages (%) of the entire study group.

The gender characteristics of the study patients are shown in Figure 2.

![Bar chart](image2.png)

Fig. 2. Gender of patients in the study groups. Results are expressed as percentages (%) of the entire study group.

The mean age of patients was 46.1 years. The age of patients in the study groups is shown in Figure 3.
Fig. 3. Age of patients in the study groups. Results are expressed as the mean ± standard deviation (SD).

An average disease onset was at the age of 27.4 years (mean age) (Figure 4), and the mean period of the disease duration was 19.3 years (Figure 5).

Fig. 4. The age of schizophrenia onset in the study groups of patients. The results are shown as means ± standard deviation (SD).
Fig. 5. The duration of the disease in the study groups of patients. The results are shown as means ± standard deviation (SD).

The mean numbers of hospitalizations of the study patients are shown in Figure 6.

Fig. 6. The number of hospitalizations in the study groups of patients. The results are shown as means ± standard deviation (SD).

The results were analyzed statistically using non-parametric Kruskal-Wallis test and Tukey HSD test for unequal sample sizes. NIR post-hoc test was also applied. Confidence interval (CI) was established at the level of 95%. The results were established as statistically significant at p<0,05.
4. Results

The intensity of negative symptoms was significantly below, as compared to the results of patients treated with neuroleptics. It was shown both in the global results of Negative Symptom Assessment Scale (NSA-16) (Figure 7) and in its sub-scales assessing alogy (Figure 8), blunted affect (Figure 9), asociality-anhedonia (Figure 10) and avolition-apathy (Figure 11).

The intensity of negative symptoms, measured with NSA-16 was 32% lower in the group of patients treated with neuroleptics, as compared with the treatment resistant subjects (Figure 7).

Fig. 7. Results of NSA-16 scale, in paranoid schizophrenia study groups of patients. Results are shown as means with standard deviation (SD). H3,162=84,7, p=0,00001, η2P=0,53.

Fig. 8. Results of NSA-16 alogy subscale, in paranoid schizophrenia study groups of patients. Results are shown as means with standard deviation (SD). H3,162=70,7, p=0,00001, η2P=0,43.
Fig. 9. Results of NSA-16 blunted affect subscale, in paranoid schizophrenia study groups of patients. Results are shown as the means with standard deviation (SD). \( H_{3,162}=65.6, \) \( p=0.00001, \eta^2_P=0.49. \)

Fig. 10. Results of NSA-16 asociality-anhedonia subscale in paranoid schizophrenia study groups of patients. Results are shown as the means with standard deviation (SD). \( H_{3,162}=60.3, \) \( p=0.00001, \eta^2_P=0.35. \)
In the avolition-apathy subscale of NSA-16, the intensity of symptoms was 39.7% lower in the group of treatment resistant schizophrenic patients (Figure 8).

In the blunted affect subscale of NSA-16, the intensity of symptoms was 26.1% lower in the patients treated with neuroleptics (Figure 9).

The intensity of symptoms, according to asociality-anhedonia subscale of NSA-16, was 35.3% higher in the treatment resistant schizophrenic patients group (Figure 10).

An analysis of the avolition-apathy subscale of NSA-16 revealed that the intensity of symptoms was 34.7% higher in the treatment resistant schizophrenia patients (Figure 11).

A clinical state of the study patients was assessed with the Clinical Global Impression–Severity (CGI-S) scale. Comparison of global clinical picture between the patients without remission and the patients effectively treated with neuroleptics revealed the significant difference (Figure 12).

In patients with remission, the intensity of the disease was assessed as minimal, but in the group of patients with residual symptoms, the intensity measured with CGI-S was moderate to severe.

An analysis of Person’s correlation coefficient has revealed that in the group of patients without remission, the severity of the symptoms correlated with the intensity of negative symptoms, measured with NSA-16 scale ($R=0.65$, $p=0.0001$). The intensity of both positive ($R=0.58$, $p=0.0001$) and negative ($R=0.37$, $p=0.0001$) symptoms, in the study groups of patients was assessed, according to Positive and Negative Syndrome Scale (PANSS).

In patients treated with haloperidol, the severity of the disease correlated significantly ($R=0.33$, $p=0.03$) with the intensity of extrapyramidal symptoms, assessed with Simpson-Angus Extrapyramidal Symptoms Scale.
Fig. 12. Assessment of clinical state of paranoid schizophrenia, in study groups of patients, with Clinical Global Impression–Severity (CGI-S) scale. Results are shown as means with standard deviation (SD). $H_{3,162}=117.3$, $p=0.0001$, $\eta^2_p=0.82$.

Cognitive dysfunctions of various intensity were present in all groups of the study patients. They included disturbances of: attention, operational memory, learning mechanisms, and reaction time. These dysfunctions were present, even though the patients met the criteria of functional remission, and were treated with neuroleptics.

An analysis of logistic regression has indicated that the cognitive deficits in subjects with schizophrenia depended on the intensity of negative symptoms and are related to the schizophrenic process. However, these symptoms did not depend on the duration of the disease, and on the age of schizophrenia onset.

5. Discussion

Many authors indicate the steady persistence of cognitive dysfunctions, during the entire schizophrenia course.

In the study by Klingberg et al. (2008), alterations of cognitive functioning among schizophrenia patients were noted over the period of 15 months. Despite improvement of memory and concentration, comparing to the beginning of the disease, after a successful treatment of the acute episode, the patient’s cognitive functioning, during the entire observation period did not return to normal level.

Also, in their 5-year study, Albus et al. (2006) indicated that the cognitive dysfunctions in schizophrenia were present from the beginning of the disease, and then, they remained stable, over the consecutive years. Both classical and atypical neuroleptics did not have any significant influence on these cognitive deficits, except from verbal fluency.

Likewise, the study by Kurtz et al. (2005), conducted on a small group of patients, indicated the presence of persistent deficits of cognitive functioning in schizophrenia, during the observation period of 10 years.

Another 10-year observation conducted by Stirling et al. (2003) has revealed that the deterioration of cognitive functioning in schizophrenia remained at a similar level during the entire duration of the disease. According to the same author, the deficit of executive...
functions was present already at the onset of the disease, and did not increase over the next 10-12 years. According to a 10-year observation by Hoff et al. (2005), it was found that the cognitive deficits had arisen prior to the first hospitalization, and subsequently lasted, without any significant deterioration, over the entire disease period. Based on the study by Øie et al. (2010), the cognitive disorders among schizophrenic patients, especially in the spectrum of verbal memory, attention, and information processing speed, remained almost unchanged, despite a 13-year period of treatment. These cognitive deficits were present, despite the improvement of clinical symptoms, over a few years, after the first schizophrenia episode (de Mello Ayres et al., 2010). The above research findings indicate that the cognitive disorders among patients with schizophrenia appear at the beginning of the disease, or even before the stage of full-blown disease, and then, they can be stable chronically.

According to contemporary standards of schizophrenia treatment, neuroleptics play the main role in therapy. Treatment starts at the beginning of an acute schizophrenia episode, when a patient meets diagnostic criteria of the disease, including fully expressed positive schizophrenia symptoms. A hypothesis of the NMDA receptors’ hypofunction and the associated cognitive disorders in schizophrenia indicate that the moment of treatment initiation is delayed by a few years.

Contemporary knowledge about cognitive disorders in schizophrenia reveals that they arise approximately 3-4 years before the first schizophrenia episode, and then, they last over the entire lifespan, at a stable level. Our study findings have confirmed the above results. The intensity of cognitive disorders among our study patients was not related to the duration of the disease. Despite an effective treatment, in patients suffering from this disease for many years, the attention disorders, operative memory deficits, as well as learning and reaction speed abnormalities persisted.

It seems that the primary cause of schizophrenia is closely related to the hypofunction of NMDA receptors. Pathogenetic process, dependent on the hypofunction of these receptors is initiated by disinhibition of neurotransmission in the OUN and hyperfrontality. Long-term effects of the glutamergic hypofunction in the OUN lead to hypofrontality, through mechanisms of neuroadaptation. Chronic persistence of cognitive dysfunctions, despite the effective symptomatic treatment indicates that the currently used neuroleptics do not normalize functions of glutamergic system. This lack of normalization of the glutamergic system activity with the neuroleptics, explains their unsatisfactory therapeutic effect on the cognitive dysfunctions in schizophrenia. Treatment of these symptoms represents a very important pharmacotherapy goal in psychiatry, because the patients’ quality of life depends mostly on the level of cognitive deficits, and intensity of negative symptoms.

According to a model of hypofunction of the NMDA receptors in schizophrenia, the treatment should already be started at the stage, in which the first cognitive disorders appear. Since the primary cause of glutamergic malfunction in schizophrenia is the hypofunction of NMDA receptors, related to GABA-ergic interneurons, the initial stage of therapy should include their stimulation, which can cause the return of inhibition of this neurotransmission in OUN. One of the considered medications in this area is acamprosate – a GABA-ergic agent, which normalizes the NMDA receptor functions and the release of glutamate (De Witte et al., 2005). In the second stage of the disease, characterized by hypofrontality and cognitive dysfunctions, the treatment should be focused on increasing
the activity of glutamergic system. In the meantime, as indicated by our study results, the neuroleptics, through altering composition of different subunits of the NMDA receptor, can reduce its activity.

It appears that the treatment strategy, which considers the model of NMDA receptor hypofunction, can create a new direction of research in psychiatry. Some proglutamergic agents, which are now under clinical investigation, may become a new generation of anti-schizophrenic drugs, in the future. They may also, like D-cycloserine - act as agonists of the NMDA receptor, or like sarcosice - inhibit the reverse uptake of glycine (Krzystanek et al., 2009).

6. Conclusion

The presented results strongly support an argument that schizophrenia may not be related to a degenerative process. The cognitive dysfunctions, as the first line of schizophrenic symptoms, can remain in schizophrenic patients for their lifetime, despite achieving clinical remission.

7. Acknowledgment

The study was funded by grant for scientific research (No KNW6-272/06) from the Ministry of Science and Higher Education in Poland. The cost of the publication was sponsored by Polpharma Biuro Handlowe Sp. z o.o.

8. References

Albus, M.; Hubmann, W.; Mohr, F.; Hecht, S.; Hinterberger-Weber, P.; Seitz, NN. & Küchenhoff, H. (2006). Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 5-year follow-up study. European Archives of Psychiatry and Clinical Neuroscience, Vol.256, No.7, (October 2006), pp.442-451, ISSN 0940-1334

Bubeníková-Valesová, V.; Horácek, J.; Vrajová, M. & Höschl, C. (2008). Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neuroscience and Biobehavioral Reviews, Vol.32, No.5, (July 2008), pp.1014-1023, ISSN 0149-7634

Carlsson, A. (2006). The neurochemical circuitry of schizophrenia. Pharmacopsychiatry, Vol.39, Suppl.1, (February 2006), pp.10-14, ISSN 0176-3679

Carter, C.S.; Perlstein, W.; Ganguli, R.; Brar, J.; Mintun, M. & Cohen, J.D. (1998). Functional hypofrontality and working memory dysfunction in schizophrenia. American Journal of Psychiatry, Vol.155, No. 9, (September 1998), pp.1285-1287, ISSN. 0002-953X

de Mello Ayres, A.; Scazuufca, M.; Menezes, P.R.; Nakano, E.Y.; Regina, A.C.; Schaufelberger, M.S.; Murray, R.M.; McGuire, P.K.; Rushe, T. & Busatto, G.F. (2010). Cognitive functioning in subjects with recent-onset psychosis from a low-middle-income environment: multiple-domain deficits and longitudinal evaluation. Psychiatry Research, Vol.179, No.2, (September 2010), pp.157-164, ISSN 0165-1781
Fuller, R.; Nopoulos, P.; Arndt, S.; O'Leary, D.; Ho, B.C. & Andreasen, N.C. (2002). Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. *American Journal of Psychiatry*, Vol.159, No.7, (July 2002), pp.1183-1189, ISSN 0002-953X

Lencz, T.; Smith, C.W.; McLaughlin, D.; Author, A.; Nakayama, E.; Hovey, L. & Cornblatt, B.A. (2006). Generalized and specific neurocognitive deficits in prodromal schizophrenia. *Biological Psychiatry*, Vol.59, No.9, (May 2006), pp.863-871, ISSN 0006-3223

Goldman-Rakic, P.S. (1999). The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. *Biological Psychiatry*, Vol.46, No.5, (September 1999), pp.650-661, ISSN 0006-3223

Hoff, A.L.; Svetina, C.; Shields, G.; Stewart, J. & DeLisi, L.E. (2005). Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. *Schizophrenia Research*, Vol.78, No.1, (October 2005), pp.27-34, ISSN 0006-3223

Homayoun, H. & Moghaddam, B. (2007). NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. *Journal of Neuroscience*, Vol.27, No.43, (October 2007), pp.11496-11500, ISSN 0270-6474

Javitt, D.C. (2010). Glutamatergic theories of schizophrenia. *The Israel Journal of Psychiatry and Related Sciences*, Vol.47, No.1, (January 2010), pp.4-16, ISSN 0333-7308

Kantrowitz, J.T. & Javitt, D.C. (2010a). N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? *Brain Research Bulletin*, Vol.83, No.3-4, (September 2010), pp.108-121, ISSN 0333-7308

Kantrowitz J.T. & Javitt, D.C. (2010b). Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models. *Clinical Schizophrenia & Related Psychoses*, Vol.4, No.3, (October 2010), pp.189-200, ISSN 1935-1232

Klasik, A.; Janas-Kozik, M.; Krupka-Matuszczyk, I. & Augustyniak, E. (2006). Funkcje poznawcze, ich rozwój oraz nowoczesne metody diagnozowania. *Przeglad Lekarski*, Vol.63, Suppl.1, (January 2006), pp.29-34, ISSN 0033-2240

Klingberg, S.; Wittorf, A.; Sickinger, S.; Buchkremer, G. & Wiedemann, G. (2008). Course of cognitive functioning during the stabilization phase of schizophrenia. *Journal of Psychiatric Research*, Vol.42, No.4, (March 2008), pp.259-267, ISSN 0022-3956

Krzystanek, M.; Palasz, A.; Krzystanek, E. & Krupka-Matuszczyk, I. (2009). Niedoczynność receptora NMDA w patogenezie schizofrenii. *Farmakoterapia w Psychiatrii i Neurologii*, Vol.25, No.3-4, (December 2009), pp.29-38, ISSN 1234-8279

Kurtz, M.M.; Seltzer, J.C.; Ferrand, J.L. & Wexler, B.E. (2005). Neurocognitive function in schizophrenia at a 10-year follow-up: a preliminary investigation. *CNS Spectrum*, Vol.10, No.4, (April 2005), pp.277-280, ISSN 1092-8529

Lieberman, J.A.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; Severe, J. & Hsiao, J.K. (2005). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *The
Neurocognitive Expression of Hypofrontality in Long Term Schizophrenia

New England Journal of Medicine, Vol.353, No.12, (September 2005), pp.1209-1223, ISSN 0028-4793

Marek, G.J.; Behl, B.; Bespalov, A.Y.; Gross, G.; Lee, Y. & Schoemaker, H. (2010). Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Molecular Pharmacology, Vol.77, No.3, (March 2010), pp.317-326, ISSN 0026-895X

Meltzer, H.Y. & McGurk, S.R. (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin, Vol.25, No.2 (March 1999), pp.233-255, ISSN 0026-895X

Øie, M.; Sundet, K. & Rund, B.R. (2010). Neurocognitive decline in early-onset schizophrenia compared with ADHD and normal controls: evidence from a 13-year follow-up study. Schizophrenia Bulletin, Vol.36, No.3, (May 2010), pp.557-565, ISSN 0026-895X

Paz, R.D.; Tardito, S.; Atzori, M. & Tseng, K.Y. (2008). Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. European Neuropsychopharmacology, Vol.18, No.11, (November 2008), pp.773-786, ISSN 0924-977X

Perkins, D.O.; Gu, H.; Boteva, K. & Lieberman, J.A. (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. American Journal of Psychiatry, Vol.162, No.10 (October 2005), pp.1785-1804, ISSN 0002-953X

Pratt, J.A.; Winchester, C.; Egerton, A.; Cochran, S.M. & Morris, B.J. (2008). Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. British Journal of Pharmacology, Vol.153, Suppl.1, (March 2008), pp.465-470, ISSN 0007-1188

Rund, B.R.; Sundet, K.; Asbjørnsen, A.; Egeland, J.; Landrø, N.I.; Lund, A.; Roness, A.; Stordal, K.I. & Hugdahl, K. (2006). Neuropsychological test profiles in schizophrenia and non-psychotic depression. Acta Psychiatrica Scandinavica, Vol.113, No.4, (April 2006), pp.350-359, ISSN 0001-690X

Seidman, L.J.; Buka, S.L.; Goldstein, J.M. & Tsuang, M.T. (2006). Intellectual decline in schizophrenia: evidence from a prospective birth cohort 28 year follow-up study. Journal of Clinical and Experimental Neuropsychology, Vol.28, No.2, (February 2006), pp.225-242, ISSN 1380-3395

Stirling, J.; White, C.; Lewis, S.; Hopkins, R.; Tantam, D.; Huddy, A. & Montague, L. (2003). Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophrenia Research, Vol.65, No.2-3, (December 2003), pp.75-86, ISSN 0006-3223

Stone, J.M.; Day, F.; Tsagaraki, H.; Valli, I.; McLean, M.A.; Lythgoe, D.J.; O’Gorman, R.L.; Barker, G.J. & McGuire, P.K.; OASIS. (2009). Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biological Psychiatry, Vol.66, No.6, (September 2009), pp.533-539, ISSN 0006-3223

Théberge, J.; Bartha, R.; Drost, D.J.; Menon, R.S.; Malla, A.; Takhar, J.; Neufeld, R.W.; Rogers, J.; Pavlosky, W.; Schaefer, B.; Densmore, M.; Al-Semaan, Y. & Williamson, P.C. (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-treated...
patients with schizophrenia and healthy volunteers. *American Journal of Psychiatry, Vol.159, No.11, (November 2002), pp.1944-1946, ISSN 0002-953X*

Thomsen, M.S.; Christensen, D.Z.; Hansen, H.H.; Redrobe, J.P. & Mikkelsen, J.D. (2009). Alpha(7) Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. *Neuropharmacology, Vol.56, No.6-7, (May-June 2009), pp.1001-1009, ISSN 0028-3908*
Due to their prevalence, pervasiveness and burden inflicted on men and women of today, psychiatric disorders are considered as one of the most important, severe and painful illnesses. This impairment of cognitive, emotional, or behavioural functioning is in some cases tragic. Aside from knowing the physical organic factors, such as infections, endocrinial illnesses or head injuries, the aetiology of psychiatric disorders has remained a mystery. However, recent advances in psychiatry and neuroscience have been successful in discovering subsequent pathophysiology and reaching associated bio-psycho-social factors. This book consists of recent trends and developments in psychiatry from all over the world, presented in the form of multifarious and comprehensive articles. The first two sections of the book are reserved for articles on schizophrenia and depression, two major illnesses present in this field. The third section of the book is reserved for addiction psychiatry, related not only to socio-cultural but also biological alterations. The last section of the book, titled Biological Neuropsychiatry, consists of three topics - updated molecular biology, fundamental neuroscience and clinical neuropsychiatric conditions. Doubtlessly, this book will be fruitful for future developments and collaboration in world psychiatry.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Marek Krzystanek, Irena Krupka-Matuszczyk and Adam Klasik (2011). Neurocognitive Expression of Hypofrontality in Long Term Schizophrenia, Psychiatric Disorders - Trends and Developments, Dr. Toru Uehara (Ed.), ISBN: 978-953-307-745-1, InTech, Available from: http://www.intechopen.com/books/psychiatric-disorders-trends-and-developments/neurocognitive-expression-of-hypofrontality-in-long-term-schizophrenia